Definition and Classification of Generic Drugs Across the World

Applied Health Economics and Health Policy

Volumn 13, Issue , 2015, Pages 5-11

  Alfonso Cristancho, Rafael ^a,c   Andia, Tatiana ^b   Barbosa, Tatiana ^c   Watanabe, Jonathan H ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c RANDOM Foundation   (Colombia)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

BIOEQUIVALENCE; DEVELOPING COUNTRY; DRUG CLASSIFICATION; DRUG DEFINITION; DRUG INDUSTRY; DRUG LEGISLATION; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; INTERVIEW; PROCEDURES; REVIEW; WORLD HEALTH ORGANIZATION; CLASSIFICATION; CULTURAL FACTOR; HEALTH CARE POLICY; HUMAN; INTERNATIONAL COOPERATION; STANDARDS; THERAPEUTIC EQUIVALENCE;

CROSS-CULTURAL COMPARISON; DEVELOPING COUNTRIES; DRUGS, GENERIC; HEALTH POLICY; HUMANS; INTERNATIONALITY; LEGISLATION, DRUG; THERAPEUTIC EQUIVALENCY; WORLD HEALTH ORGANIZATION;

EID: 84938415214     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0146-1     Document Type: Review

References (23)

1. World Health Organization. How to develop and implement a national drug policy. World Health Organization; 2001.
2. Laing R, Waning B, Gray A, Ford N, t Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003;361(9370):1723–9.
3. Attridge CJ, Alexander SP. Improving access to medicines in developing countries. Washington, DC: The World Bank; 2005.
4. World Health Organization. WHO model list of essential medicines: 18th list. 2013.
5. Opderbeck DW. Patents, essential medicines, and the innovation game. Vand L Rev. 2005;58:501.
6. World Health Organization. How to develop and implement a national drug policy. Geneva: World Health Organization; 2001.
7. Nardi R, Masina M, Cioni G, Leandri P, Zuccheri P. Generic-equivalent drugs use in internal and general medicine patients: distrust, confusion, lack of certainties or of knowledge? Part 2. Misconceptions, doubts and critical aspects when using generic drugs in the real world. Ital J Med. 2014;8(2):88–98.
8. Bate R, Jin GZ, Mathur A. Does price reveal poor-quality drugs? Evidence from 17 countries. J Health Econ. 2011;30(6):1150–63.
9. Sheppard A. Generic medicines: essential contributors to the long-term health of society. IMS health. http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf. Accessed 27 Jan 2015.
10. Gorokhovich LE, Chalkidou K, Shankar R. Improving access to innovative medicines in emerging markets: evidence and diplomacy as alternatives to the unsustainable status quo. J Health Dipl. 2013;1(1).
11. Shargel L, Isadore K, editors. Generic drug product development: solid oral dosage forms. CRC Press; 2013.
12. Shah US. Regulatory strategies and lessons in the development of biosimilars. In: Pharmaceutical sciences encyclopedia. Wiley; 2010. doi:10.1002/9780470571224.pse511.
13. Mastan S, Latha TB, Ajay S. The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies-an overview. Comp Eff Res. 2011;1:1–25.
14. Kanavos Panos, Costa-Font Joan, Seeley Elizabeth. Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy. 2008;23(55):499–544.
15. Grabowski HG. Chapter 8: competition between generic and branded drugs. Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective. 2007, p. 153–288. http://hdl.handle.net/10161/7370.
16. World Population Growth. World Bank Report. http://www.worldbank.org/depweb/beyond/beyondco/beg_03.pdf. Accessed 27 Jan 2015.
17. Seiter A. A practical approach to pharmaceutical policy. World Bank Publications; 2010.
18. Vacca González CP, Fitzgerald JF, Bermúdez JAZ. Definición de medicamento genérico ¿un fin o un medio? Análisis de la regulación en 14 países de la Región de las Américas. Rev Panam Salud Publica. 2006;20(5):314–23.
19. Vacca C, Claudia V, Martín C, Ludovic R. Publicidad y promoción de medicamentos: regulaciones y grado de acatamiento en cinco países de América Latina; Drug advertising and promotion: regulations and extent of compliance in five Latin American countries. Rev panam salud pública. 2011;29(2):76–83
20. WHO National Medicines List/Formulary/Standard Treatment Guidelines. http://www.who.int/selection_medicines/country_lists/en/#K. Accessed 27 Jan 2015.
21. Nguyen TA, Hassali MA, McLachlan A. Generic medicines policies in the Asia Pacific region: ways forward. WHO South-East Asia J Public Health. 2013;2:72–4.
22. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries–an overview. Generics Biosimilars Initiat J. 2012;1(2):44–51.
23. Shukla N, Sangal T. Generic drug industry in India: the counterfeit spin. J Intellect Propierty Rights. 2009;14:236–240